Bacterial characteristics of carbapenem-resistant Enterobacteriaceae (CRE) colonized strains and their correlation with subsequent infection
- PMID: 34215214
- PMCID: PMC8254368
- DOI: 10.1186/s12879-021-06315-0
Bacterial characteristics of carbapenem-resistant Enterobacteriaceae (CRE) colonized strains and their correlation with subsequent infection
Abstract
Background: Searching the risk factors for carbapenem-resistant Enterobacteriaceae (CRE) infection is important in clinical practice. In the present study, we aim to investigate bacterial characteristics of colonizing strains and their correlation with subsequent CRE infection.
Methods: Between May 2018 and January 2019, patients hospitalized in the department of haematology and intensive care unit (ICU) were screened for CRE by rectal swabs and monitored for the outcome of infection. We identified the species and carbapenemase-encoding genes of colonizing strains and performed antimicrobial susceptibility tests and multilocus sequence typing (MLST). Risk factors for subsequent CRE infections were ascertained by univariate and multivariable analysis.
Results: We collected a total of 219 colonizing strains from 153 patients. Klebsiella pneumoniae was the most abundant species, and MLST analysis showed rich diversity. K. pneumoniae carbapenemase (KPC) was predominant in the infection group (72.4%). In the non-infection group, 35.4% of strains were non-carbapenemase-producing CRE (NCP-CRE), and New Delhi metallo-β-lactamase (NDM) was predominant (42.2%). The rate of high-level carbapenem resistance (minimum inhibitory concentration [MIC] ≥ 64 mg/L for meropenem and ertapenem, ≥ 32 mg/L for imipenem) was remarkably higher in the infection group than in the non-infection group (P < 0.001). Univariate analysis showed that K. pneumoniae, high-level carbapenem resistance, CP-CRE and KPC-CRE were infection risk factors after CRE colonization. On multivariable analysis with different carbapenemase dichotomizations, KPC-CRE (adjusted odds ratio [aOR], 4.507; 95% confidence interval [CI], 1.339-15.171; P = 0.015) or imipenem MIC ≥ 32 mg/L (aOR, 9.515; 95% CI, 1.617-55.977; P = 0.013) were respectively identified as independent risk factors for subsequent infection.
Conclusions: Patients colonized with KPC-CRE or strains with an imipenem MIC ≥ 32 mg/L were at particularly high risk of subsequent CRE infections during their hospital stay.
Keywords: Bacterial characteristic; Carbapenem-resistant Enterobacteriaceae; Intestinal colonization; Risk factor.
Conflict of interest statement
The authors have no competing interests to declare.
Figures


Similar articles
-
Molecular characterization of carbapenem-resistant Enterobacteriaceae and emergence of tigecycline non-susceptible strains in the Henan province in China: a multicentrer study.J Med Microbiol. 2021 Mar;70(3):001325. doi: 10.1099/jmm.0.001325. Epub 2021 Feb 15. J Med Microbiol. 2021. PMID: 33587030 Free PMC article.
-
Phenotypic and Genotypic Characterization of Carbapenem-resistant Enterobacteriaceae: Data From a Longitudinal Large-scale CRE Study in China (2012-2016).Clin Infect Dis. 2018 Nov 13;67(suppl_2):S196-S205. doi: 10.1093/cid/ciy660. Clin Infect Dis. 2018. PMID: 30423057
-
Imipenem/relebactam activity compared to other antimicrobials against non-MBL-producing carbapenem-resistant Enterobacteriaceae from an academic medical center.Pathog Dis. 2019 Jun 1;77(4):ftz040. doi: 10.1093/femspd/ftz040. Pathog Dis. 2019. PMID: 31365075
-
Meropenem/vaborbactam: a next generation β-lactam β-lactamase inhibitor combination.Expert Rev Anti Infect Ther. 2020 Jul;18(7):643-655. doi: 10.1080/14787210.2020.1756775. Epub 2020 May 3. Expert Rev Anti Infect Ther. 2020. PMID: 32297801 Review.
-
A Systematic Review and Meta-analyses of the Clinical Epidemiology of Carbapenem-Resistant Enterobacteriaceae.Antimicrob Agents Chemother. 2017 Dec 21;62(1):e01730-17. doi: 10.1128/AAC.01730-17. Print 2018 Jan. Antimicrob Agents Chemother. 2017. PMID: 29038269 Free PMC article.
Cited by
-
An analysis of differences in Carbapenem-resistant Enterobacterales in different regions: a multicenter cross-sectional study.BMC Infect Dis. 2024 Jan 22;24(1):116. doi: 10.1186/s12879-024-09005-9. BMC Infect Dis. 2024. PMID: 38254025 Free PMC article.
-
Antimicrobial and Anti-Biofilm Activity of Dichlorophen-Functionalized Gold Nanoparticles Against Carbapenem-Resistant Enterobacteriaceae.Int J Nanomedicine. 2025 Aug 25;20:10255-10277. doi: 10.2147/IJN.S532807. eCollection 2025. Int J Nanomedicine. 2025. PMID: 40896802 Free PMC article.
-
Phage-Plasmids Spread Antibiotic Resistance Genes through Infection and Lysogenic Conversion.mBio. 2022 Oct 26;13(5):e0185122. doi: 10.1128/mbio.01851-22. Epub 2022 Sep 26. mBio. 2022. PMID: 36154183 Free PMC article.
-
ST11 Carbapenem-Resistant Klebsiella pneumoniae Clone Harboring blaNDM Replaced a blaKPC Clone in a Tertiary Hospital in China.Antibiotics (Basel). 2022 Oct 7;11(10):1373. doi: 10.3390/antibiotics11101373. Antibiotics (Basel). 2022. PMID: 36290031 Free PMC article.
-
Trends in DTR, CR, ECR, and FQR in Four Common Gram-Negative Bacteria: A Retrospective Study from 2013 to 2021.Infect Drug Resist. 2022 May 23;15:2625-2631. doi: 10.2147/IDR.S365139. eCollection 2022. Infect Drug Resist. 2022. PMID: 35634581 Free PMC article.
References
-
- Dickstein Y, Edelman R, Dror T, Hussein K, Bar-Lavie Y, Paul M. Carbapenem-resistant Enterobacteriaceae colonization and infection in critically ill patients: a retrospective matched cohort comparison with non-carriers. J Hosp Infect. 2016;94(1):54–59. doi: 10.1016/j.jhin.2016.05.018. - DOI - PubMed
-
- Schwaber MJ, Lev B, Israeli A, Solter E, Smollan G, Rubinovitch B, Shalit I, Carmeli Y. Israel Carbapenem-resistant Enterobacteriaceae working G: containment of a country-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention. Clin Infect Dis. 2011;52(7):848–855. doi: 10.1093/cid/cir025. - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous